Compare Albemarle Corp. (ALB) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albemarle Corp. vs Novavax Inc — how do they compare? Albemarle Corp. trades at $128.35 (market cap $15.27B), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Albemarle Corp. is far larger — about 11.7× Novavax Inc's market cap, and Albemarle Corp. pays a 1.27% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| ALB | NVAX | |
|---|---|---|
Market Cap | $15.27B | $1.31B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $11.19 |
52-Week Low | $72.58 | $6.22 |
Enterprise Value | $17.75B | $889.30M |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) trades at $128.29, down 2.23% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company reported strong Q2 2026 results with EPS of $3.75 beating estimates by 17%, driven by improved lithium pricing and specialty chemicals performance. Despite recent profitability challenges with negative net income in 2025, cash flow generation remains healthy at $1.28B from operations.
Analyst consensus leans positive with 42% buy ratings and $184.50 price target representing 44% upside potential. Key risks include lithium price volatility and Q3 margin pressure, while catalysts include sustained demand for energy storage solutions and ongoing balance sheet improvements through debt reduction.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
